(ACRV) Acrivon Therapeutics, Inc. Business Model Canvas Research

Acrivon Therapeutics, Inc. relies on proteomics and assay vendors because AP3 depends on specialized instruments and lab inputs to generate protein-level data for OncoSignature diagnostics. These partners help turn complex assay results into a precision medicine workflow that supports target selection and patient stratification.

• AP3 needs specialist proteomics tools
• Vendors supply assay reagents and inputs
• Protein data feeds OncoSignature models
• Supports precision medicine decisions

Acrivon Therapeutics, Inc. pairs its drug programs with companion diagnostics, so it needs diagnostic labs and regulatory advisers to keep biomarker tests aligned with clinical design, FDA paths, and later launch plans. That support matters because Acrivon’s lead assets are still in clinical development, so test strategy must move in step with each trial readout.

• External assay design and validation
• Regulatory guidance for co-development
• Links biomarkers to trials and launch

Acrivon Therapeutics, Inc. uses pipeline target discovery to widen its reach beyond ACR-368, with early work in DNA damage response and cell-cycle regulation. The focus on WEE1 and PKMYT1 adds at least 2 high-value kinase targets, helping reduce single-asset risk and build a broader oncology pipeline.

• Beyond ACR-368

• WEE1 and PKMYT1 targets

• Broader pipeline optionality

Acrivon Therapeutics, Inc. must keep regulatory filings, chemistry, manufacturing and controls work, and patent coverage tight to move its clinical programs forward and protect future approvals. This is especially important because its drug and diagnostic platforms rely on the same defensible IP and CMC package to support both clinical execution and later commercial value.

• Maintain FDA-ready filings
• Prove CMC consistency
• Protect drug and diagnostic IP

Acrivon Therapeutics, Inc. uses two early DDR and cell-cycle programs, WEE1 and PKMYT1, to widen its pipeline beyond the lead asset. Both targets sit in the DNA damage response network that regulates cell division, giving the Company 2 follow-on shots at high-value oncology biology.

• 2 early pipeline programs
• WEE1 and PKMYT1 targets
• DDR and cell-cycle control pathways

Acrivon Therapeutics, Inc., founded in 2018 and based in Watertown, Massachusetts, relies on its scientific team and HQ as a core resource. That human base supports discovery, clinical development, and biomarker analysis, which is central to its platform-led biotech model.

• Founded in 2018
• Headquartered in Watertown, Massachusetts
• Scientific staff drives discovery and trials
• Biomarker work supports platform execution

Acrivon Therapeutics, Inc.’s OncoSignature companion diagnostics are built to enrich trials and later treatment use by identifying likely responders, which can lift the odds of clinical success and support a tighter go-to-market plan. In 2025, the company reported a market cap near $200 million and used this biomarker-led approach to focus development spend on the patients most likely to benefit.

• Enriches trials with responder-focused enrollment
• Can improve development success odds
• Supports more efficient commercial targeting

Acrivon Therapeutics, Inc. is not built around one target: its DDR portfolio spans CHK1/CHK2, WEE1, and PKMYT1 biology, giving it three parallel shots on goal in DNA damage response and cell-cycle control. That spread can reduce single-program risk and gives the company more ways to reach tumor types that depend on replication stress.

• CHK1/CHK2, WEE1, and PKMYT1
• Three distinct DDR angles
• Less reliance on one asset

Acrivon Therapeutics, Inc. uses peer-reviewed papers and conference talks to share AP3 and ACR-368 data with clinicians, researchers, and investors, which helps build trust in its precision oncology platform. This kind of scientific engagement turns trial results into clear proof points, so the market can judge the pipeline on data, not claims.

• Shares AP3 and ACR-368 results
• Reaches clinicians and researchers
• Supports investor confidence
• Builds awareness of the platform

Acrivon’s trial relationships are built on biomarker and clinical readouts, so sites and investigators get rapid feedback on patient selection and study performance. That creates a tight learning loop around the platform, with each enrolled patient improving the next decision.

• Biomarker data guides enrollment
• Sites get performance feedback
• Each trial improves the model

Acrivon Therapeutics, Inc. can use direct business development outreach to target diagnostics, licensing, and co-development partners, starting with scientific and commercial diligence. This matters because Acrivon is still a clinical-stage company with no approved products, so partner deals are a key route to future value capture and non-dilutive funding.

• Target diagnostics and licensing partners
• Start with scientific diligence
• Then test commercial fit
• Use deals to capture future value

Companion diagnostics need a clear channel from biomarker discovery to assay development and clinical use, and Acrivon Therapeutics, Inc.’s AP3-to-OncoSignature workflow is that bridge. It links internal tumor biology work to patient selection in the clinic, which matters because Acrivon had no product revenue in its latest reported period while advancing one lead platform toward real-world use.

• AP3 finds biomarker signals
• OncoSignature converts them into an assay
• Clinical use closes the loop

Biopharma licensing partners are B2B buyers that can license Acrivon Therapeutics, Inc.’s AP3 biomarker tools or pipeline assets, helping extend the platform beyond internal drug development. This segment can speed external validation and future monetization, especially as Acrivon Therapeutics, Inc. advances programs in a market where biotech licensing deals often run into the tens or hundreds of millions of dollars.

• AP3 tools can be licensed
• Pipeline assets can be partnered
• Supports non-dilutive monetization

Pathology and diagnostic labs are key customers because Acrivon Therapeutics, Inc.'s companion diagnostics must be run, read, and validated in lab workflows before they can support treatment decisions. In the U.S., CLIA oversight covers 300,000+ laboratory entities, so lab groups matter both for assay validation and for scaling commercialization.

• Run companion diagnostics
• Validate lab performance
• Support commercialization

Manufacturing and supply are a real cash drain for Acrivon Therapeutics, Inc.: drug substance and clinical drug product must be made under GMP quality rules, and small-molecule oncology trials often need costly batch, packaging, and cold-chain logistics. As enrollment expands from dozens to hundreds of patients, supply spend can rise fast; Phase 2 oncology programs can burn tens of millions of dollars before any revenue.

• GMP drug substance and drug product
• Clinical packaging and distribution
• Higher spend as trials scale up

As a public, clinical-stage biotech, Acrivon Therapeutics, Inc. carries G&A costs for staff, legal, finance, IP protection, and SEC/reporting work. Compliance overhead is not optional; in FY2025, that burden rose with public-company controls, audit work, and regulatory support tied to ongoing clinical development.

• People, legal, finance, IP
• SEC, audit, and controls
• Meaningful cash drain for biotech

Acrivon Therapeutics, Inc.'s OncoSignature companion diagnostics could add revenue if the test is commercialized, since biomarker-guided patient selection is a natural fit for its drug pipeline. In its latest 2025 reporting, Acrivon remained pre-commercial, so any diagnostic sales would be a new, higher-margin stream tied to each treated patient.

• Tests can be sold with therapy access
• Biomarkers support patient selection
• Revenue scales with test adoption

That makes companion diagnostics a direct way to monetize clinical insight, not just drug sales.

Acrivon Therapeutics, Inc. can earn royalties if it licenses the AP3 platform or out-licenses pipeline assets, which matters because the Company is still pre-commercial and reported no product revenue in its latest filings. For a platform biotech, even one partnered program can turn future milestones plus royalties into recurring, higher-margin income.

• AP3 licensing can create royalty upside.
• Partnerships fit a pre-commercial model.
• Royalties can compound over time.